Inhibitors in AKTion: ATP-competitive vs allosteric
Sign Up to like & getrecommendations! Published in 2020 at "Biochemical Society Transactions"
DOI: 10.1042/bst20190777
Abstract: Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target.… read more here.
Keywords: atp competitive; inhibitors aktion; aktion atp; competitive allosteric ... See more keywords